
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio Inc. has demonstrated consistent clinical benefits in patients receiving RGX-202 treatment, with improvements observed at 9 and 12 months that favorably compare to natural history data, indicating strong therapeutic potential. The company has also shown durable treatment effects from its therapy sura-vec, with stable or improved vision up to four years, suggesting long-term efficacy in target diseases. Additionally, the scalable manufacturing capabilities of Regenxbio position it favorably for potential revenue generation, while the encouraging interim data from the AFFINITY DUCHENNE trial further strengthen the outlook for the company's gene therapy pipeline.
Bears say
Regenxbio Inc faces significant risks related to potential delays in data releases, which could adversely influence investor sentiment and prompt downward revisions of revenue estimates. The challenges associated with developing adequate manufacturing capacity for its complex AAV-based gene therapies could further constrain financial forecasts and hinder product commercialization efforts. Additionally, the possibility of regulatory setbacks stemming from safety concerns poses an ongoing risk that may negatively impact the company’s future performance in the gene therapy market.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares